AI Article Synopsis
- Vemurafenib, a BRAF kinase inhibitor, was tested in a phase 3 trial showing over 50% response rates in patients with metastatic melanoma carrying the BRAF V600E mutation.
- The trial compared vemurafenib and dacarbazine in 675 patients, focusing on overall and progression-free survival, with significant interim results favoring vemurafenib.
- At 6 months, 84% of patients on vemurafenib survived compared to 64% on dacarbazine, leading to a recommendation for dacarbazine patients to switch to vemurafenib due to its safety profile and higher response rates.
Article Abstract
Background: Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.
Methods: We conducted a phase 3 randomized clinical trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation. Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area intravenously every 3 weeks). Coprimary end points were rates of overall and progression-free survival. Secondary end points included the response rate, response duration, and safety. A final analysis was planned after 196 deaths and an interim analysis after 98 deaths.
Results: At 6 months, overall survival was 84% (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group. In the interim analysis for overall survival and final analysis for progression-free survival, vemurafenib was associated with a relative reduction of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine (P<0.001 for both comparisons). After review of the interim analysis by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended. Response rates were 48% for vemurafenib and 5% for dacarbazine. Common adverse events associated with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% of patients required dose modification because of toxic effects.
Conclusions: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation. (Funded by Hoffmann-La Roche; BRIM-3 ClinicalTrials.gov number, NCT01006980.).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549296 | PMC |
| http://dx.doi.org/10.1056/NEJMoa1103782 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The paradoxical activity of BRAF inhibitors: potential use in wound healing.
Arch Dermatol Res
January 2025
Department of Translational & Clinical Research, School of Chemical and Life Sciences, Jamia Hamdard, Hamdard Nagar, New Delhi, 110062, India.
The area of wound healing presents a promising field of interest for clinicians as well as the scientific community. A major concern for physicians is the rising number of elderly people suffering from diabetes, leprosy, tuberculosis and the associated chronic wounds. While traditional therapies target basic wound care, innovative strategies that accelerate wound healing are needed.
View Article and Find Full Text PDFBRAF-mutant melanoma management: a single center retrospective analysis of patients treated with sequential therapy.
Melanoma Manag
December 2024
Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", Sapienza University of Rome, Latina, Italy.
Aims: In treating patients with melanoma, the order in which therapy is administered, choosing between targeted therapy and immune checkpoint inhibition, has garnered growing interest.
Patients And Methods: We conducted a retrospective, real-world analysis of patients with advanced melanoma undergoing immunotherapy or targeted therapy as first-line at a single center.
Results: A total of 88 patients diagnosed with melanoma were identified.
Is there still a place for lymph node dissection for stage III melanoma since the approval of adjuvant therapy.
Curr Opin Oncol
January 2025
Department of Medical Oncology, Institut Jules Bordet - Université Libre de Bruxelles (ULB).
Purpose Of Review: This review aims to explore the evolving management strategies for stage III melanoma, focusing on the comparative effectiveness of traditional surgical approaches like complete lymph node dissection (CLND) versus modern adjuvant therapies. It also examines the latest evidence on the efficacy, risks, and complications of these strategies, emphasizing the role of shared decision-making between patients and clinicians.
Recent Findings: Recent clinical trials and meta-analyses, including the MSLT-II and DeCOG-SLT studies, have demonstrated that CLND may not significantly improve survival outcomes in melanoma patients with sentinel lymph node biopsy (SLNB)-positive status.
Neoadjuvant or perioperative immunotherapy for resectable melanoma: The need for biomarkers.
Eur J Cancer
January 2025
National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark. Electronic address:
Groundbreaking studies have reshaped the treatment landscape for patients with resectable stage ≥IIIB melanoma by demonstrating the benefits of neoadjuvant therapy. Data from the NADINA and SWOG S1801 trials reveal substantial improvements in event-free survival compared to adjuvant therapy alone. These studies employed distinct neoadjuvant immunotherapy approaches - ipilimumab plus nivolumab in NADINA and anti-PD-1 monotherapy in SWOG S1801 - highlighting potential differences in efficacy and toxicity.
View Article and Find Full Text PDFNivolumab and hypofractionated radiotherapy in patients with advanced melanoma: A phase 2 trial.
Eur J Cancer
January 2025
Department of Dermatology, Côte d'Azur University, University Hospital Center of Nice, France.
Background: Radiotherapy is thought to enhance anti-tumor immunity, particularly when delivered in a hypofractionated and multisite manner. Therefore, we investigated the effects of combining radiotherapy with nivolumab in patients with advanced melanoma.
Methods: This was a multicenter, non-randomized, phase 2 trial that enrolled patients with treatment-naïve metastatic melanoma.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!